Relapse and rehospitalization: comparing oral and depot antipsychotics.
about
Relapse and hospitalization in patients with schizophrenia and bipolar disorder at the St Amanuel Mental Specialized Hospital, Addis Ababa, Ethiopia: a comparative quantitative cross-sectional studyDepot Typical Antipsychotics versus Oral Atypical Antipsychotics in Relapse Rate Among Patients with Schizophrenia: A Five -Year Historical Cohort StudyEffectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium.Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study resultsLong-acting antipsychotic drugs for the treatment of schizophrenia: use in daily practice from naturalistic observations.Schizophrenia symptoms and functioning in patients receiving long-term treatment with olanzapine long-acting injection formulation: a pooled analysisThe role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.A rapid method for creating drug implants: translating laboratory-based methods into a scalable manufacturing processRelapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial.Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophreniaSwitching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database.Using films as a psychoeducation tool for patients with schizophrenia: a pilot study using a quasi-experimental pre-post design.The Potential Role of Long-acting Injectable Antipsychotics in People with Schizophrenia and Comorbid Substance Use.Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults.Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia.Enhancing adherence, subjective well-being and quality of life in patients with schizophrenia: which role for long-acting risperidone?Psychoeducation in schizophrenia--results of a survey of all psychiatric institutions in Germany, Austria, and SwitzerlandOutpatient antipsychotic treatment and inpatient costs of schizophreniaLong-acting injectable antiretrovirals for HIV treatment and preventionTreatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidoneA pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection.Development of novel risperidone implants using blends of polycaprolactones and in vitro in vivo correlation studies.Efficacy of psychological therapy in schizophrenia: conclusions from meta-analyses.Long-term remission in schizophrenia and schizoaffective disorder: results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE).Long-acting injectable antipsychotics in first-episode schizophrenia.Management of antipsychotic treatment discontinuation and interruptions using model-based simulations.Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection.
P2860
Q33817913-2AC762F1-F6FC-4124-B221-CC5ED1B3EAA2Q33834476-66794F2B-EC5A-4918-BDED-1C39E9A1E35DQ33862078-6305E631-9152-4A73-9F6A-6E2D1DF05C6DQ34048194-1CC7C4F1-2267-4A89-9E7F-754AE8ED277FQ34386881-FA934AED-CD8E-4D92-B77A-1A87F72E47D0Q34398243-4B24DF0D-C88B-4D9C-910F-AE9DE02FB7BAQ34418847-3B1855FC-5DF2-4AC7-B302-FD3FA7388E39Q34629537-D3375157-DDD3-4495-B628-F5EA41F7D253Q34660553-4FF1219F-6C71-4EDD-8F4F-925B17506059Q35186007-28AA4784-2977-4F68-8E96-865D8FFB1246Q35249595-F24555FF-E5B7-4195-9825-D16AE50E02FDQ35577308-7569C19B-FDA6-4C7C-B7BC-339259D0F74AQ36059843-197950C7-1DFF-49E5-B133-64C4B5D3793EQ36144552-3B4F01A4-3D9D-4BAA-8A4A-007B1974FD17Q36202865-79E9D241-4361-49C3-B875-99535E2E0D9BQ36211694-C9BEEE5E-C6B8-4780-88FB-318A0F836736Q36537792-DBD9709A-FDED-40B0-9018-DC6E5E68310AQ37076234-F4375AB5-5F4B-4E85-8B8F-3E10E1F17562Q37272776-4CE4501C-5084-4085-842E-8EF24F01A282Q37427122-83F60EE0-486F-4000-9414-59BA96BBBCE9Q37501165-FAD176AE-7248-4A9B-A82E-3453197A99E9Q40952775-AD146219-77BD-40F8-A45A-D2FE12AC55FDQ41875383-DB1C8B25-302A-43FE-8921-1417599B8B79Q41899147-51706028-3B9D-4089-A68B-136EDBE0A618Q41991738-3B88F472-916C-494E-96D4-F079387C28D0Q42149681-8AC7AE72-617C-4C18-9D05-692C506FE409Q42520005-8C52C5B7-7ABB-40B8-AB4B-5266B9D8C06A
P2860
Relapse and rehospitalization: comparing oral and depot antipsychotics.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Relapse and rehospitalization: comparing oral and depot antipsychotics.
@ast
Relapse and rehospitalization: comparing oral and depot antipsychotics.
@en
type
label
Relapse and rehospitalization: comparing oral and depot antipsychotics.
@ast
Relapse and rehospitalization: comparing oral and depot antipsychotics.
@en
prefLabel
Relapse and rehospitalization: comparing oral and depot antipsychotics.
@ast
Relapse and rehospitalization: comparing oral and depot antipsychotics.
@en
P1476
Relapse and rehospitalization: comparing oral and depot antipsychotics
@en
P2093
Nina R Schooler
P478
64 Suppl 16
P577
2003-01-01T00:00:00Z